Often, novel gene and cell therapies provide hope for many people living with incurable diseases. To facilitate and accelerate a successful regulatory approval and commercialization path for effective, safe and affordable cell and gene therapies, the involvement of patient advocacy groups (PAGs) should be considered early in the development process. This report provides a thorough overview of the various roles PAGs play in the clinical translation of cell and gene therapies and how they can bring about positive changes in the regulatory process, infrastructure improvements and market stability.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jcyt.2016.10.017 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!